I reported previously (May 2017) that Israel’s UroGen Pharma had been granted FDA’s Orphan status for its treatment of malignant Upper Tract Urothelial Carcinoma. It has now received Breakthrough Therapy Designation status to help speed up development.

http://investors.urogen.com/phoenix.zhtml?c=254372&p=irol-newsArticle&ID=2374119